What the trials show, what they do not, and the reasons someone should not go. Written to be checked: the studies are named, and the numbers are the ones the papers report.
The modern evidence is small, careful and — so far — encouraging. Every trial below gave psilocybin with psychological support before, during and after: screened participants, trained sitters, preparation sessions, integration sessions. That is not a detail. No trial has tested the drug without the therapy, and the results belong to the pair.
Put together: for depression and for the distress of serious illness, the effect in supervised, supported settings is real and often large, and it appears quickly. The trials are small, the follow-up is mostly months rather than years, blinding is imperfect because people can tell what they took, and every participant was screened and supported. Anyone who tells you the science is settled is selling something. Anyone who tells you there is nothing there has not read it.
Long before the trials, everyone who worked with these substances knew that the mind you bring (set) and the place and people around you (setting) shape what happens as much as the substance does. The research agrees. In a large prospective study of people about to take psychedelics, how prepared they felt, how clear their intention was, and how they rated the setting predicted both a better experience and better wellbeing afterward; the dose mattered less than people assume. Haijen et al., 2018, Frontiers in Pharmacology. The Imperial group's summary is the plainest statement of it: context is not incidental to the effect; it is part of the mechanism. Carhart-Harris et al., 2018, Journal of Psychopharmacology.
That is the whole argument for the first and second parts of what we do. Preparation is set. The facilitator, the provider and the room are setting.
Every trial included integration sessions; almost none isolated their effect, and the reviews say so — integration is the piece the field agrees matters and has barely measured. We are honest about this: our claim for integration rests on the trials' design, on the set-and-setting literature, and on seventy years of Frankl's method, not on a trial of integration by itself. What we can promise is that the method is built for it. Logotherapy has always held that a feeling, however profound, is not yet a meaning; a meaning is something done in the world. That is exactly the translation integration has to make.
Every trial excluded people, and for good reasons. We use the same exclusions, and the psychologist applies them before anything else happens:
Even for people who pass screening, hard experiences are common. In a large survey of people who had had a difficult psilocybin experience, about one in thirteen had sought help for psychological symptoms afterward, and a small number had put themselves or others at physical risk during it — mostly when alone or unprepared. Carbonaro et al., 2016, Journal of Psychopharmacology. Persistent visual changes and long-lasting distress are rare but real. None of this is a reason for panic; it is the reason for a screened, prepared, accompanied, integrated process — and against buying something from a stranger and taking it alone.